Leerink Partnrs Forecasts Q32 Bio FY2029 Earnings

Q32 Bio Inc. (NASDAQ:QTTB) – Equities research analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for Q32 Bio in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings per share of ($0.75) for the year. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Q32 Bio’s current full-year earnings is ($12.32) per share.

Several other equities analysts have also recently commented on QTTB. Wells Fargo & Company reiterated an “equal weight” rating and set a $16.00 target price (down from $95.00) on shares of Q32 Bio in a research note on Wednesday, December 11th. Piper Sandler reduced their price objective on shares of Q32 Bio from $85.00 to $20.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 11th. Guggenheim downgraded shares of Q32 Bio from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 11th. Leerink Partners restated a “market perform” rating and issued a $9.00 target price (down previously from $68.00) on shares of Q32 Bio in a research note on Wednesday, December 11th. Finally, Raymond James reiterated an “outperform” rating and issued a $22.00 price target (down from $90.00) on shares of Q32 Bio in a research note on Wednesday, December 11th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Q32 Bio currently has an average rating of “Moderate Buy” and an average target price of $29.86.

Q32 Bio Trading Down 0.3 %

Shares of QTTB opened at $3.15 on Friday. Q32 Bio has a one year low of $2.90 and a one year high of $53.79. The stock has a 50-day moving average price of $6.86 and a 200 day moving average price of $29.27. The company has a debt-to-equity ratio of 0.61, a quick ratio of 6.53 and a current ratio of 6.53. The company has a market capitalization of $38.37 million, a P/E ratio of -0.22 and a beta of -0.32.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC acquired a new position in Q32 Bio during the 2nd quarter valued at about $265,000. Values First Advisors Inc. bought a new stake in shares of Q32 Bio during the third quarter valued at about $33,000. FMR LLC lifted its stake in shares of Q32 Bio by 137.3% in the 3rd quarter. FMR LLC now owns 426,302 shares of the company’s stock worth $19,022,000 after acquiring an additional 246,664 shares during the period. BNP Paribas Financial Markets lifted its position in Q32 Bio by 199.1% in the third quarter. BNP Paribas Financial Markets now owns 1,298 shares of the company’s stock worth $58,000 after purchasing an additional 864 shares during the period. Finally, MetLife Investment Management LLC acquired a new stake in shares of Q32 Bio in the third quarter valued at $159,000. Institutional investors and hedge funds own 31.32% of the company’s stock.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.